January 10, 2019
On January 3, 2019, Takeda announced multiple research collaborations involving the development of chimeric antigen receptor T-cell (CAR-T) therapies for various cancers, and the company is working with Memorial Sloan Kettering Cancer Center (MSKCC) on the approach.1 One of the therapies under investigation is for the treatment of multiple myeloma. “We are excited by the recent momentum...
Continue Reading

Floor 7, 90 The Terrace
Wellington Central
New Zealand